While personalized medicine is what we at Diaceutics eat, sleep, and breathe, that’s not the case for everyone else, whether they be in pharma or just generally interested in health care, medicine and science. Luckily, we’ve got everyone covered. Now that we’re well into the second half of 2016, we’ve rounded up the top personalized medicine posts of the year so far so to keep you up to date on the important stuff.
A great dive into the possibilities provided by major technological advances in genomics, this is a must read for anyone interested in PM. Don’t be intimidated by the text-heavy content, this post moves quickly through several major points in a very effective way.
I loved this article as it is short and to the point – but more importantly it helps to send the message of personalized medicine to a much wider audience than the technical pharmaceutical reader.
This is not so much a post as it is an article reporting the highly fascinating results of a study. The study was based on “24 anticancer drugs tested against a large number of cell lines in order to understand the relation between drug resistance and altered genomic features of a cancer cell line.” In hopes of promoting patient-specific anticancer drugs and to aid the scientific community, the creators of this study have developed a tool for “predicting priority/potency of an anticancer drug against a cancer cell line using its genomic features.” The tool is called CancerDP and can be found at this address: http://crdd.osdd.net/raghava/cancerdp/
I’m an analytical person and I love data, which made this article my favorite of the bunch. Getting granular with big data is possible, but to reach this point there are many technical hurdles that must be overcome, including data collection, data storage, and most importantly turning the stores of data into actionable insights.
Gastrointestinal Stromal Tumors, or GIST, is resistant to conventional chemotherapy drugs and radiation. This article takes a detailed look at how targeted therapies may help to overcome the many challenges care providers are faced when treating GIST.
As there is limited research regarding the most aggressive forms of hepatoblastoma, this article details many of the challenges faced in the availability of tissue and cell lines required to develop targeted therapies. While a solution is challenging to find, the problem is very well defined by this study.